J. Jansat

发表

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

E. G. Gil, R. Lamarca, E. Garcia Gil, 2009, International journal of clinical pharmacology and therapeutics.

Ion Mobility–Mass Spectrometry for Bioanalysis

S. Sentellas, J. Jansat, X. Garcia, 2021, Separations.

Pharmacokinetic and Pharmacodynamic Studies of the Histamine H1‐Receptor Antagonist Ebastine in Dogs

A. Martinez-Tobed, A. Puigdemont, M. Queralt, 1994, The Journal of pharmacy and pharmacology.

Sensitive UHPLC-MS/MS method for the determination of tacrolimus in minipig whole blood.

S. Sentellas, J. Jansat, M. Álvarez, 2020, Bioanalysis.

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

C. Caracta, K. Lasseter, E. Garcia Gil, 2012, Pulmonary pharmacology & therapeutics.

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial

B. Piraccini, U. Blume-Peytavi, F. Scarci, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

S. de la Motte, E. G. Gil, K. Schmid, 2012, International journal of clinical pharmacology and therapeutics.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

C. Caracta, E. G. Gil, Fanying Li, 2012, Biopharmaceutics & drug disposition.

Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long‐Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants

R. Lamarca, J. Jansat, G. Miquel, 2009, Journal of clinical pharmacology.

Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial.

J. Costa, A. Martinez-Tobed, J. Jansat, 2006, International journal of clinical pharmacology and therapeutics.

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

J. Fleishaker, N. Azie, D. Bell, 2001, British journal of clinical pharmacology.

No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P‐glycoprotein (P‐gp) drug transporter

J. Aubets, J. Jansat, M. Salvà, 2019, Pharmacology research & perspectives.

Absolute Bioavailability, Pharmacokinetics, and Urinary Excretion of the Novel Antimigraine Agent Almotriptan in Healthy Male Volunteers

P. Salvà, Joan Costa, A. Martinez-Tobed, 2002, Journal of clinical pharmacology.

Almotriptan, a new anti-migraine agent: a review.

J. Palacios, J. Gras, J. Llenas, 2006, CNS drug reviews.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

R. Pauwels, H. Magnussen, G. Joos, 2010, Respiratory medicine.

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.

R. Pauwels, G. Joos, J. Jansat, 2010, British Journal of Clinical Pharmacology.

Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum.

Magnus Knutsson, Hans Mulder, Pierre Boulanger, 2009, Bioanalysis.

Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan.

J. Palacios, A. Martinez-Tobed, J. Jansat, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Disposition and metabolism of almotriptan in rats, dogs and monkeys

J. Palacios, A. Martinez-Tobed, J. Aubets, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods.

J. Jansat, E. Mariño, C. Lastra, 1996, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

K. Schmid, S. Pascual, J. Jansat, 2010, Clinical therapeutics.

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants

C. Caracta, Stephen Flach, J. Jansat, 2012, Journal of clinical pharmacology.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

E. G. Gil, K. Schmid, S. Pascual, 2010, Clinical therapeutics.

Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm2 : A Phase 1 Maximal-Use Trial in Patients with Actinic Keratosis.

J. Jansat, R. Otero, Janet DuBois, 2024, Clinical pharmacology in drug development.